Antihemophilic factor inhibitors. Management with prothrombin complex concentrates

Area of Science:

• Hematology
• Coagulation Disorders
• Immunology

Background:

• Factor VIII inhibitors complicate hemophilia treatment, leading to acute bleeding episodes.
• Current treatment options for patients with factor VIII inhibitors are limited.
• Prothrombin complex concentrates (PCCs) are used to manage bleeding in hemophilia.

Purpose of the Study:

• To evaluate the efficacy of prothrombin complex concentrates in treating acute bleeding in patients with factor VIII inhibitors.
• To assess the impact of PCCs on inhibitor levels and factor VIII responsiveness.

Main Methods:

• Retrospective analysis of 11 hemophilic and 2 nonhemophilic patients with factor VIII inhibitors.
• Treatment with prothrombin complex concentrates (Proplex) for acute bleeding episodes.
• Monitoring of inhibitor levels and factor VIII response during concentrate use.

Main Results:

• PCCs were effective in managing acute bleeding episodes.
• Continued use of Proplex led to a decrease in inhibitor levels in several hemophilic patients.
• One hemophilic patient became responsive to factor VIII therapy after prolonged PCC treatment.

Conclusions:

• Prothrombin complex concentrates are a viable therapeutic option for patients with factor VIII inhibitors.
• The mechanism of action may involve activated factors or in vivo factor Xa generation.
• PCCs offer an effective alternative until high-potency activated products become widely available.